In the short run, the decision will render rulemaking far less predictable, which could have a destabilizing effect on drug and device manufacturing, major health providers, and public health efforts.
Experts note that judges will increasingly set aside regulations following the repeal of the Chevron deference doctrine, leading to court interpretations over executive branch decisions.
Justice Elena Kagan's dissenting opinion highlighted potential ramifications for Medicare payment adjustments and regulatory discretion, emphasizing a shift toward courts influencing healthcare policy.
Collection
[
|
...
]